Rexahn Pharmaceuticals, Inc. (REXN)
REXN Stock Price Chart
|Net Income (ttm)||-6.37M|
|Trading Day||Nov 5, 2020|
|Day's Range||1.72 - 1.93|
|52-Week Range||1.70 - 3.70|
REXN Stock News
Rexahn Pharmaceuticals Announces Expected Effectiveness of Reverse Stock Split and Merger Transaction with Ocuphire Pharma
ROCKVILLE, Md., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) (“Rexahn”) announced today that the merger transaction between Rexahn and Ocuphire Pharma, Inc. is ...
Rexahn Pharmaceuticals Announces Stockholder Approval of All Proposals Required for Merger with Ocuphire Pharma
ROCKVILLE, Md., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) (“Rexahn”) announced today that at its special meeting of stockholders held on November 2, 2020, Re...
Rexahn Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether The Merger Of Rexahn Pharmaceuticals, Inc. Is Fair To Shareholders; Investors Are Encouraged To Contact The Firm
NEW YORK, June 29, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger between Rexahn Pharmaceuticals, Inc. (NASDAQ: REXN) and Ocuphir...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Merger of Rexahn Pharmaceuticals, Inc. with Ocuphire Pharma, Inc.
New York, New York--(Newsfile Corp. - June 22, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Rexahn Pharmaceuticals, Inc. (...
Transaction to Create a Nasdaq-listed Biopharmaceutical Company Focused on Advancing Ocuphire’s Late-Stage Clinical Pipeline of Ophthalmic Drug Candidates
Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of cancer. The company's product pipeline include RX-3117, which is in Phase IIa clinical trials for the treatment of patients with relapsed or refractory metastatic pancreatic cancer, as well as bladder, colon, lung and cervical cancer. It is also developing RX-0301, which is in preclinical development stage for the treatment of hepatocellular carcinoma. Rexahn Pharmaceuticals, Inc. has collaboration agreements with Zhejiang Haichang ... [Read more...]
Douglas J. Swirsky
|Stock Exchange |
|Ticker Symbol |